ALSO NOTED: Ipsen files new BLA;Amgen selects Vectibix test; and much more...

> Ipsen says it has submitted a new BLA for Reloxin, addressing concerns raised by the FDA when the agency declined to file its BLA in January. Release

> Amgen says it will use Lab21's diagnostic test to see which patients are suitable for its cancer drug Vectibix. Report

> NanoBio Corporation reported that a Phase IIb study of NB-001, a topical lotion to treat cold sores, met its primary and secondary endpoints by demonstrating clear efficacy and safety in 482 patients. Release

> The FDA is hustling up new programs designed to shore up confidence in drug safety--and in its own ability to ensure it. Report

> Pay for the CEOs of Wyeth and Pfizer was down in 2007. Report

> The wrestling match in Biovail's boardroom is getting ugly. Founder and former CEO Eugene Melnyk called for a housecleaning on the company's board. Report

> Rumor Mill: Less than 10 days after CEO Jeffrey Kindler pooh-poohed big acquisitions, U.K. markets are awash with rumors that Pfizer is on the hunt for British pharma group Shire. Report

And Finally... A fresh controversy over tainted drugs may be just what the FDA needs to win new federal funding. Article

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.